Full Data
?
UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on the Chinese Stock Markets
Join Now!
Need this critical market data?
Access thousands of market events, data points, and news articles!
Already have an account?
Login
Home » News » Zhongsheng Ruichuang's 3CL protease inhibitor clinical trial application was accepted by NMPA, and domestic new crown drugs accelerated